Project title: Biosafety assays for the diagnosis and prediction of drug-related complement pathology
Minimising allergic reactions to intravenous immunotherapies with new biosafety testing
Drug development proceeds along a regulated pathway from innovation and research to preclinical and clinical trials to review by national authorities. Many drugs do not make it through clinical trials due to unpredicted adverse side effects in people. Others make it through, despite the side effects, when these are deemed of low enough risk or incidence. For many therapies administered intravenously, infusion reactions (IRs) are common, particularly among immunotherapeutics. Even though these can be severe and even life-threatening, assaying for allergic IRs before a drug gets to clinical phases is challenging because relevant biomarkers or animal models are scarce. EU funding of the Biosafety project is building capacity at Hungary’s Semmelweis University with the goal of addressing this problem to enhance the safety of immunotherapeutics for patients who need them.
NEXT CONFERENCE
10-11 July 2023 (Budapest, Hungary)- BIOSAFETY Project Meeting and Final Conference
INVITATION TO TENDER (call for young researchers to support participation in international conferences)
The grant will cover the participation fee, accommodation, and travel costs for international scientific conferences to be held between 01.04.2023 and 31.07.2023. Priority will be given to applications related to the theme of the Biosafety programme and for applicants having a first-authored oral or poster presentation.
This project has received funding
from the European Union’s
Horizon 2020 research and innovation programme
under grant agreement No. 952520